 Following the breakthrough deal with GlaxoSmithKline, Spero is in a comfortable position to advance its pipeline. The 150 million non-performance related milestone payment, equivalent to 3.2 per share, associated with Phase 3 clinical trial provides sufficient upside from todays share price. 